Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2009 Jan 7;40(12):603–610. [Article in Spanish] doi: 10.1016/S0212-6567(08)75693-2

Influencia de la morbilidad y uso de recursos en pacientes que demandan atención por trastorno de ansiedad generalizada en el ámbito de la atención primaria de salud☆☆☆

Influence of morbidity and the use of health resources in patients who require care for generalised anxiety disorder in the primary health care setting

Antoni Sicras-Mainar a,⁎, Milagrosa Blanca-Tamayo b, Ruth Navarro-Artieda c, Israel Pizarro-Paixa d, Susana Gómez-Lus Centelles e
PMCID: PMC7713261  PMID: 19100147

Abstract

Objective

To evaluate the co-morbidity, health care use, economical impact, and availability of effective treatments used in generalised anxiety disorder (GAD) patients in a primary care setting (PCS).

Method

A retrospective multicentre population-based study.

Setting

Five primary care clinics managed by Badalona Serveis Assistencials S.A., Barcelona, Spain.

Participants

Outpatient records of patients over 18 years managed at 5 PCSs during 2006. Patients with and without GAD were compared. In GAD patients, 4 groups were established for comparison, according to pharmacological prescription.

Measurements

Main outcomes measures were general, reason/co-morbidity, health care use and primary care cost (visits, diagnostic/therapeutic tests, and drugs).We counted work absenteeism as an indirect cost. Pharmacological prescription was studied according to evidence-based recommendations and Spanish health-approved indications. The statistical analysis included a multivariate model: logistic regression, analysis of covariance (ANCOVA), P<.05.

Results

Of the 65 767 patients included, 4.6% (95% confidence interval [CI], 3.9-5.3) had GAD. Patients with/without GAD, the average episode/year was 6.1 versus 4.7 and attendance/year 10.0 versus 7.6; P<.001.GAD was associated with women (odds ratio [OR], 1.8), dyslipidemia (OR, 1.2), smoking (OR, 1.4), depression (OR, 1.2), and cerebrovascular accident (OR, 1.6) (P<.02). The mean direct cost/year adjusted by age, gender and morbidity load was €686 versus €557 (P<.001). GAD was associated with higher directs costs. The recommended treatment was followed in 40.1% of total patients (95% CI, 38.4-41.8).

Conclusions

Patients with GAD have greater co-morbidity and higher direct costs in PCS. Means designed to improve the recognition and treatment of these patients should be established in the PCS.

Key words: Generalised anxiety disorder, Resources uses, Health care costs, Primary care

Footnotes

☆

El trabajo ha sido parcialmente financiado por Lundbeck y el Fondo de Investigaciones Sanitarias de la Seguridad Social (PI05/2837).

☆☆

Confidencialidad de la información: En todo momento se respetó la confidencialidad marcada por la ley.

Bibliografía

  • 1.Ansseau M., Fischler B., Dierick M., Mignon A., Leyman S. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur Psychiatry. 2005;20:229–235. doi: 10.1016/j.eurpsy.2004.09.035. [DOI] [PubMed] [Google Scholar]
  • 2.Kessler R.C., Chiu W.T., Demler O., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–627. doi: 10.1001/archpsyc.62.6.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ruscio A.M., Chiu W.T., Roy-Byrne P., Stang P.E., Stein D.J., Wittchen H.U. Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. J Anxiety Disord. 2007;21:662–676. doi: 10.1016/j.janxdis.2006.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mergl R., Seidscheck I., Allgaier A.K., Möller H.J., Hegerl U., Henkel V. Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition. Depress Anxiety. 2007;24:185–195. doi: 10.1002/da.20192. [DOI] [PubMed] [Google Scholar]
  • 5.Craske M.G., Waters A.M. Panic disorder, phobias, and generalized anxiety disorder. Annu Rev Clin Psychol. 2005;1:197–225. doi: 10.1146/annurev.clinpsy.1.102803.143857. [DOI] [PubMed] [Google Scholar]
  • 6.Roy-Byrne P.P., Wagner A. Primary care perspectives on generalized anxiety disorder. J Clin Psychiatry. 2004;65(Suppl 13):20–26. [PubMed] [Google Scholar]
  • 7.Kendler K.S., Walters E.E., Neale M.C., Kessler R.C., Heath A.C., Eaves L.J. The structure of the genetic and environmental risk factors for six major psychiatric disorders in women. Phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism. Arch Gen Psychiatry. 1995;52:374–383. doi: 10.1001/archpsyc.1995.03950170048007. [DOI] [PubMed] [Google Scholar]
  • 8.Zhao X.H., Wang P.J., Li C.B., Wang J.H., Yang Z.Y., Hu Z.H. Prefrontal and superior temporal lobe hyperactivity as a biological substrate of generalized anxiety disorders. Zhonghua Yi Xue Za Zhi. 2006;86:955–960. [PubMed] [Google Scholar]
  • 9.Grant B.F., Hasin D.S., Stinson F.S., Dawson D.A., June Ruan W., Goldstein R.B. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35:1747–1759. doi: 10.1017/S0033291705006069. [DOI] [PubMed] [Google Scholar]
  • 10.Allen L.A., Gara M.A., Escobar J.I., Waitzkin H., Silver R.C. Somatization: a debilitating syndrome in primary care. Psychosomatics. 2001;42:63–67. doi: 10.1176/appi.psy.42.1.63. [DOI] [PubMed] [Google Scholar]
  • 11.Munk-Jorgensen P., Allgulander C., Dahl A.A., Foldager L., Holm M., Rasmussen I. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr Serv. 2006;57:1738–1744. doi: 10.1176/ps.2006.57.12.1738. [DOI] [PubMed] [Google Scholar]
  • 12.Rodríguez B.F., Weisberg R.B., Pagano M.E., Bruce S.E., Spencer M.A., Culpepper L. Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis. 2006;194:91–97. doi: 10.1097/01.nmd.0000198140.02154.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kessler R.C., Berglund P.A., Dewit D.J., Ustün T.B., Wang P.S., Wïttchen H.U. Distinguishing generalized anxiety disorder from major depression: prevalence and impairment from current pure and comorbid disorders in the US and Ontario. Int J Methods Psychiatr Res. 2002;11:99–111. doi: 10.1002/mpr.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kroenke K., Spitzer R.L., Williams J.B., Monahan P.O., Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity and detection. Ann Intern Med. 2007;146:317–325. doi: 10.7326/0003-4819-146-5-200703060-00004. [DOI] [PubMed] [Google Scholar]
  • 15.Wittchen H.U., Hoyer J., Beesdo K., Krause P. Problems and deficiencies in family physician's management of generalized anxiety disorders. Results of the GAD-P study and priorities for an improved care. Fortschr Med Orig. 2001;119(Suppl 1):42–49. [PubMed] [Google Scholar]
  • 16.Goodwin R.D., Jacobi F., Thefeld W. Mental disorders and asthma in the community. Arch Gen Psychiatry. 2003;60:1125–1130. doi: 10.1001/archpsyc.60.11.1125. [DOI] [PubMed] [Google Scholar]
  • 17.Honda K., Goodwin R.D. Cancer and mental disorders in a national community sample: findings from the National Comorbidity Survey. Psychother Psychosom. 2004;73:235–242. doi: 10.1159/000077742. [DOI] [PubMed] [Google Scholar]
  • 18.Henning E.R., Turk C.L., Mennin D.S., Fresco D.M., Heimberg R.G. Impairment and quality of life in individuals with generalized anxiety disorder. Depress Anxiety. 2007;24:342–349. doi: 10.1002/da.20249. [DOI] [PubMed] [Google Scholar]
  • 19.Sareen J., Jacobi F., Cox B.J., Belik S.L., Clara I., Stein M.B. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med. 2006;166:2109–2116. doi: 10.1001/archinte.166.19.2109. [DOI] [PubMed] [Google Scholar]
  • 20.Boulenger J.P., Capdevielle D. Pharmacological treatment of generalized anxiety disorders: rationale and limitations. Encephale. 2007;33:84–94. doi: 10.1016/s0013-7006(07)91562-6. [DOI] [PubMed] [Google Scholar]
  • 21.Tyrer P., Baldwin D. Generalised anxiety disorder. Lancet. 2006;368:2156–2166. doi: 10.1016/S0140-6736(06)69865-6. [DOI] [PubMed] [Google Scholar]
  • 22.Barsky A.J., Orav E.J., Bates D.W. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry. 2005;62:903–910. doi: 10.1001/archpsyc.62.8.903. [DOI] [PubMed] [Google Scholar]
  • 23.Wittchen H.U. Generalized anxiety disorder: prevalence, burden and cost to society. Depress Anxiety. 2002;16:162–171. doi: 10.1002/da.10065. [DOI] [PubMed] [Google Scholar]
  • 24.Andlin-Sobocki P., Wittchen H.U. Cost of anxiety disorders in Europe. Eur J Neurol. 2005;12(Suppl 1):39–44. doi: 10.1111/j.1468-1331.2005.01196.x. [DOI] [PubMed] [Google Scholar]
  • 25.American Psychiatric Association . 4.ª ed. American Psychiatric Association; Washington,DC: 1994. Diagnostic and Statistical Manual of Mental Disorders. [Google Scholar]
  • 26.First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. American Psychiatric Press; Washington,DC: 1996. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version: Administration Booklet. [Google Scholar]
  • 27.Lamberts H., Wood M., Hofmans-Okkes I.M., editors. The International Classification of Primary Care in the European Community. With a multi-language layer. Oxford University Press; Oxford: 1993. [Google Scholar]
  • 28.Charlson M.E., Pompei P., Ales K.L., Mackenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi: 10.1016/0021-9681(87)90171-8. [DOI] [PubMed] [Google Scholar]
  • 29.The Johns Hopkins ACG® Case-mix System version 7.0-April, 2005. Baltimore: Johns Hopkins Bloomberg School of Public Health; 2005.
  • 30.Weiner J.P., Starfield B.H., Steinwachs D.M., Mumford L.M. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care. 1991;29:452–472. doi: 10.1097/00005650-199105000-00006. [DOI] [PubMed] [Google Scholar]
  • 31.Guidelines for ATC classification. Oslo: Nordic Collaborating Centre for Drug Statistics Methodology; 1991.
  • 32.Canadian Psychiatric Association Clinical Practice Guidelines: Management of Anxiety Disorders. Can J Psychiatry. 2006;51(8 Suppl 2):9S–91S. Fe de errors: Can J Psychiatry. 2006; 51(10):623. [PubMed] [Google Scholar]
  • 33.GPT-1 Guía de Prescripción Terapéutica . Pharma Editores; Barcelona: 2006. Agencia Española de Medicamentos y Productos Sanitarios. Ministerio de Sanidad y Consumo. [Google Scholar]
  • 34.García-Cardona F., Molins-Pérez G., Farré-Pradell J., Martín-Sánchez A., Pané-Mena O., Gallego-Español R. Cost accountability in primary care: list of services. Aten Primaria. 1995;16:141–145. [PubMed] [Google Scholar]
  • 35.Ansseau M., Dierick M., Buntinkx F., Cnockaert P., De Smedt J., Van Den Haute M. High prevalence of mental disorders in primary care. J Affect Disord. 2004;78:49–55. doi: 10.1016/s0165-0327(02)00219-7. [DOI] [PubMed] [Google Scholar]
  • 36.The ESEMeD/MHEDEA 2000 investigators Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;109(Suppl 420):21–27. doi: 10.1111/j.1600-0047.2004.00327.x. [DOI] [PubMed] [Google Scholar]
  • 37.Van Vliet I.M., De Beurs E. The MINI-International Neuropsychiatric Interview. A brief structured diagnostic psychiatric interview for DSM-IV en ICD-10 psychiatric disorders. Tijdschr Psychiatr. 2007;49:393–397. [PubMed] [Google Scholar]
  • 38.Olfson M., Gameroff M.J. Generalized anxiety disorder, somatic pain and health care costs. Gen Hosp Psychiatry. 2007;29:310–316. doi: 10.1016/j.genhosppsych.2007.04.004. [DOI] [PubMed] [Google Scholar]
  • 39.Olssøn I., Mykletun A., Dahl A.A. Recognition and treatment recommendations for generalized anxiety disorder and major depressive episode: A cross-sectional study among general practitioners in Norway. J Clin Psychiatry. 2006;8:340–347. doi: 10.4088/pcc.v08n0604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19:567–596. doi: 10.1177/0269881105059253. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES